Knowing who is at high risk in the near term could make it easier to conduct trials of anti-thrombotic therapies. Developed by Protagonist Therapeutics, rusfertide is a novel injectable synthetic mimetic of the natural hormone hepcidin. Mass spectrometry–based proteomics were used to learn more about how MKs drive bone marrow fibrosis. Prevalence of symptoms was assessed with the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score. Adults older than 65 and newly diagnosed with DLBCL or DLBCL/high-grade BCL with MYC and BCL2 rearrangements were surveyed. There was previously a gap in evidence when it came to how the drug works after treatment with covalent BTK inhibitors. The retrospective study evaluated if pacritinib increased PLT counts in the phase III PERSIST-2 and phase II PAC203 studies. Researchers examined registry data for patients with previously untreated DLBCL or high-grade BCL treated with R-CHOP. The model could be helpful in understanding fibrotic progression in JAK2V617F mutation–positive MPNs. Extrachromosomal DNA was highly expressed in 18 DLBCL cell lines and may function as a powerful prognostic indicator.